Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi: 10.1016/S0140-6736(16)32126-2
   PubMed Web of Science ®Google Scholar
• Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18(7):1356–1363. doi: 10.1002/ibd.22839
   PubMed Web of Science ®Google Scholar
• Nakase H, Sato N, Mizuno N, et al. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2022;21(3):103017. doi: 10.1016/j.autrev.2021.103017
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. doi: 10.1038/s41572-020-0205-x
   PubMed Web of Science ®Google Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–1794.e4. doi: 10.1053/j.gastro.2011.01.055
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. International Organization for the Study of IBD. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–1201. doi: 10.1053/j.gastro.2011.06.054
   PubMed Web of Science ®Google Scholar
• Travis SPL, Higgins PDR, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;34(2):113–124. doi: 10.1111/j.1365-2036.2011.04701.x
   PubMed Web of Science ®Google Scholar
• Bryant RV, Winer S, Travis SPL, et al. Systematic review: histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 2014;8(12):1582–1597. doi: 10.1016/j.crohns.2014.08.011
   PubMed Web of Science ®Google Scholar
• Neri B, Mossa M, Scucchi L, et al. Histological scores in inflammatory bowel disease. J Dig Dis. 2021;22(1):9–22. doi: 10.1111/1751-2980.12937
   PubMed Web of Science ®Google Scholar
• Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013;11(12):1601–1608.e4. doi: 10.1016/j.cgh.2013.06.023
   PubMed Web of Science ®Google Scholar
• Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133(4):1099–1105. doi: 10.1053/j.gastro.2007.08.001
   PubMed Web of Science ®Google Scholar
• Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451–459. doi: 10.1053/j.gastro.2003.11.010
   PubMed Web of Science ®Google Scholar
• Shehab M, Al Akram S, Hassan A, et al. Histological disease activity as predictor of clinical relapse, hospitalization, and surgery in inflammatory bowel disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2023 Aug 4;30(4): 563–572. doi: 10.1093/ibd/izad119. Online ahead of print. PMID: 37541185.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Fiorino G, Solitano V, et al. Ulcerative colitis: impact of early disease clearance on long-term outcomes – a multicenter cohort study. United Eur Gastroenterol J. 2022;10(7):775–782. doi: 10.1002/ueg2.12288
   PubMed Web of Science ®Google Scholar
• Dal Buono A, Roda G, Argollo M, et al. Histological healing: should it be considered as a new outcome for ulcerative colitis? Expert Opin Biol Ther. 2020;20(4):407–412. doi: 10.1080/14712598.2020.1701652
   PubMed Web of Science ®Google Scholar
• Argmann C, Hou R, Ungaro RC, et al. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut. 2023;72(7):1271–1287. doi: 10.1136/gutjnl-2021-326451
   PubMed Web of Science ®Google Scholar
• Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. doi: 10.1093/ecco-jcc/jjab178
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y, et al.; AGA Institute clinical guidelines committee. Aga clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–1461. doi: 10.1053/j.gastro.2020.01.006
   PubMed Web of Science ®Google Scholar
• Travis SP, Jewell DP. Salicylates for ulcerative colitis – their mode of action. Pharmacol Ther. 1994;63(2):135–161. doi: 10.1016/0163-7258(94)90042-6
   PubMed Web of Science ®Google Scholar
• Spinelli A, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohns Colitis. 2022;16(2):179–189. doi: 10.1093/ecco-jcc/jjab177
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106. doi: 10.1136/gutjnl-2019-318484
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi: 10.1056/NEJMoa050516
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut. 2011;60(6):780–787. doi: 10.1136/gut.2010.221127
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–265.e1–3. doi: 10.1053/j.gastro.2011.10.032
   Web of Science ®Google Scholar
• GEMINI 1 Study Group, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• UNIFI Study Group, Sands BE, Sandborn WJ, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE sustain investigators. Tofacitinib as Induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736. doi: 10.1056/NEJMoa1606910
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–2128. doi: 10.1016/S0140-6736(22)00581-5
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372–2384. doi: 10.1016/S0140-6736(21)00666-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf Dc, et al. Touchstone Study Group. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016;374(18):1754–1762.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135. doi: 10.1038/ctg.2015.63
   PubMed Web of Science ®Google Scholar
• Singh J, Wells G, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;CD008794. doi: 10.1002/14651858.CD008794.pub2
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Panes J, Sands BE, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019;50(10):1068–1076. doi: 10.1111/apt.15514
   PubMed Web of Science ®Google Scholar
• Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–170. doi: 10.1016/S2468-1253(21)00377-0
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, Jaks, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36. doi: 10.1038/nrrheum.2015.167
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, et al. The jaK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66(1):311–328. doi: 10.1146/annurev-med-051113-024537
   PubMedGoogle Scholar
• Clark JD, Flanagan ME, Telliez JB. Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038. doi: 10.1021/jm401490p
   PubMed Web of Science ®Google Scholar
• Gordon H, Burisch J, Ellul P, et al. ECCO Guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1–37. doi: 10.1093/ecco-jcc/jjad108
   PubMed Web of Science ®Google Scholar
• Dhaliwal G, Patrone MV, Bickston SJ. Venous thromboembolism in patients with inflammatory bowel disease. J Clin Med. 2023;13(1):251. doi: 10.3390/jcm13010251
   PubMed Web of Science ®Google Scholar
• Singh A, Goyal MK, Midha V, et al. Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial. Am J Gastroenterol. 2024 Jan 22. doi: 10.14309/ajg.0000000000002635. Online ahead of print. PMID: 38131615.
   Google Scholar
• Lichtenstein GR, Rogler G, Ciorba MA, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancy (excluding nonmelanoma skin cancer) events across the ulcerative colitis clinical program. Inflam Bowel Dis. 2021;27(6):816–825. doi: 10.1093/ibd/izaa199
   PubMed Web of Science ®Google Scholar
• Sands BE, Long MD, Reinisch W, et al. Tofacitinib for the treatment of ulcerative colitis: analysis of nonmelanoma skin cancer rates from the ulcerative colitis clinical program. Inflamm Bowel Dis. 2022;28(2):234–245. doi: 10.1093/ibd/izab056
   PubMed Web of Science ®Google Scholar
• Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75(5):831–841. doi: 10.1136/annrheumdis-2014-205847
   PubMed Web of Science ®Google Scholar
• Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554–1573.e12. doi: 10.1053/j.gastro.2020.01.001
   PubMed Web of Science ®Google Scholar
• Gordon H, Biancone L, Fiorino G, et al. ECCO Guidelines on Inflammatory Bowel disease and malignancies. J Crohns Colitis. 2023;17(6):827–854. doi: 10.1093/ecco-jcc/jjac187
   PubMed Web of Science ®Google Scholar
• Núñez P, Quera R, Yarur AJ. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases. Drugs. 2023;83(4):299–314. doi: 10.1007/s40265-023-01840-5
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review. Drugs. 2020;80(11):1085–1100. doi: 10.1007/s40265-020-01346-4
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Robinson C, Bernaslo N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Inflamm Bowel Dis. 2019;25(4):627–641. doi: 10.1093/ibd/izz037
   PubMed Web of Science ®Google Scholar
• Pugliese D, Privitera G, Gisbert JP, et al. New drugs for the treatment of IBD during conception, pregnancy, and lactation. Dig Liver Dis. 2024;56(2):235–241. doi: 10.1016/j.dld.2023.08.054
   PubMedGoogle Scholar
• Mahadevan U, Dubinsky MC, Su C, et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24(12):2494–2500. doi: 10.1093/ibd/izy160
   PubMed Web of Science ®Google Scholar
• Xeljanz: EPAR. n.d. 2023; https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf
   Google Scholar
• Rinvoq: EPAR; 2023 n.d. https://www.ema.europaeu/en/documents/productinformation/rinvoq-epar-product-information_en.pdf
   Google Scholar
• Jyseleca: EPAR; 2023 n.d. https://www.ema.europa.eu/en/documents/productinformation/jyseleca-epar-product-information_en.pdf
   Google Scholar
• Na L, Zhong-Ping G, Shuang-Qing D, et al. Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis. Clin Rheumatol. 2022;41(3):677–688. doi: 10.1007/s10067-021-06003-z
   PubMed Web of Science ®Google Scholar
• Imamura E, Taguchi K, Sasaki-Iwaoka H, et al. Anti-IL-23 receptor monoclonal antibody prevents CD. Eur J Pharmacol. 2018;824:163–169. doi: 10.1016/j.ejphar.2018.01.045
   PubMedGoogle Scholar
• Armuzzi A, Cross RK, Lichtenstein GR, et al. Cardiovascular safety of ozanimod in patients with ulcerative colitis: true north and open-label extension analyses. Clin Gastroenterol Hepatol. 2023;S1542–3565(23)00956–4. doi: 10.1016/j.cgh.2023.11.018
   Web of Science ®Google Scholar
• Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550–561. doi: 10.1053/j.gastro.2019.10.035
   PubMed Web of Science ®Google Scholar
• Vermeire S, Chiorean M, Panés J, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohns Colitis. 2021;15(6):950–959. doi: 10.1093/ecco-jcc/jjab016
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Watanabe M, Motoya S., et al. AJM300 Study Group. Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients with Active Ulcerative Colitis. Gastroenterology. 2015;149(7):1775–1783.
   PubMed Web of Science ®Google Scholar
• Apolit C, Campos N, Vautrin A, et al. ABX464 (Obefazimod) upregulates miR-124 to reduce proinflammatory markers in inflammatory bowel diseases. Clin Transl Gastroenterol. 2023;14(4):e00560. doi: 10.14309/ctg.0000000000000560
   PubMed Web of Science ®Google Scholar
• Vermeire S, Hébuterne X, Tilg H, et al. ABX464 Investigators. Induction and Long-term Follow-up with ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial. Gastroenterology. 2021;160(7):2595–2598. doi: 10.1053/j.gastro.2021.02.054
   PubMed Web of Science ®Google Scholar
• Xu H, Jesson MI, Seneviratne UI, et al. PF-06651600, a dual JAK3/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235–1242. doi: 10.1021/acschembio.9b00188
   PubMed Web of Science ®Google Scholar
• Fensome A, Ambler CM, Arnold E, et al. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1] octan-8-yl)methanone (PF-06700841). J Med Chem. 2018;61(19):8597–8612. doi: 10.1021/acs.jmedchem.8b00917
   PubMed Web of Science ®Google Scholar
• Telliez JB, Dowty ME, Wang L, et al. Discovery of a JAK3- selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):3442–3451. doi: 10.1021/acschembio.6b00677
   PubMed Web of Science ®Google Scholar
• Robinson MF, Damjanov N, Stamenkovic B, et al. Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2020;72(10):1621–1631. doi: 10.1002/art.41316
   PubMed Web of Science ®Google Scholar
• Poggi A, Benelli R, Venè R, et al. Human gut-associated natural killer cells in health and disease. Front Immunol. 2019;10:961. doi: 10.3389/fimmu.2019.00961
   PubMed Web of Science ®Google Scholar
• Casalegno Garduño R, Däbritz J. New Insights on CD8+ T Cells in Inflammatory Bowel Disease and Therapeutic Approaches. Front Immunol. 2021;12:738762. doi: 10.3389/fimmu.2021.738762
   PubMed Web of Science ®Google Scholar
• Andreotti AH, Schwartzberg PL, Joseph RE, et al. T-cell signaling regulated by the Tec family kinase, Itk. Cold Spring Harb Perspect Biol. 2010;2(7):a002287–a002287. doi: 10.1101/cshperspect.a002287
   PubMed Web of Science ®Google Scholar
• Guan D, Wang Z, Huo J, et al. Bruton’s tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response. Cell Death Dis. 2021;12(5):431. doi: 10.1038/s41419-021-03702-y
   PubMed Web of Science ®Google Scholar
• Lechner K, Mott S, Al-Saifi R, et al. Targeting of the Tec Kinase ITK Drives Resolution of T Cell–Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis. Gastroenterology. 2021;161(4):1270–1287.e19. doi: 10.1053/j.gastro.2021.06.072
   PubMed Web of Science ®Google Scholar
• Weeks S, Harris R, Karimi M. Targeting ITK signaling for T cell-mediated diseases. iScience. 2021;24(8):102842. doi: 10.1016/j.isci.2021.102842
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–1709. doi: 10.1016/S0140-6736(17)30570-6
   PubMed Web of Science ®Google Scholar
• Eftychi C, Schwarzer R, Vlantis K, et al. Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment. Immunity. 2019;51:367–380.e4. doi: 10.1016/j.immuni.2019.06.008
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Danese S, Leszczyszyn J, et al. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results from a Randomized, Phase 2b Study. Clin Gastroenterol Hepatol. 2023;21(10):2616–2628. doi: 10.1016/j.cgh.2022.12.029
   PubMed Web of Science ®Google Scholar
• Hassan-Zahraee M, Ye Z, Xi L, et al. Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis. J Crohns Colitis. 2023 Dec 23;jjad213.doi: 10.1093/ecco-jcc/jjad213. Online ahead of print.PMID: 38141256.
   PubMed Web of Science ®Google Scholar
• Beattie DT, Pulido-Rios MT, Shen F, et al. Intestinally-restricted janus kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy. J Inflamm (Lond). 2017;14(1):28. doi: 10.1186/s12950-017-0175-2
   PubMedGoogle Scholar
• Sandborn WJ, Nguyen DD, Beattie DT, et al. Development of gut-selective pan-janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme. J Crohns Colitis. 2020;14(9):1202–1213. doi: 10.1093/ecco-jcc/jjaa049
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/study/NCT03758443
   Google Scholar
• https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-announces-top-line-results-phase-2b
   Google Scholar
• Argollo M, Furfaro F, Gilardi D, et al. Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther. 2020;20(4):413–420. doi: 10.1080/14712598.2020.1732919
   PubMed Web of Science ®Google Scholar
• Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015;125(4):1379–1387. doi: 10.1172/JCI76369
   PubMed Web of Science ®Google Scholar
• Pérez-Jeldres T, Tyler CJ, Boyer JD, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists. Front Pharmacol. 2019;10:212. doi: 10.3389/fphar.2019.00212
   PubMed Web of Science ®Google Scholar
• Karuppuchamy T, Tyler CJ, Lundborg LR, et al. Sphingosine-1-phosphate lyase inhibition alters the S1P gradient and ameliorates Crohn’s-like ileitis by suppressing thymocyte maturation. Infamm Bowel Dis. 2020;26(2):216–228. doi: 10.1093/ibd/izz174
   PubMed Web of Science ®Google Scholar
• Aoki M, Aoki H, Ramanathan R, et al. Sphingosine-1-phosphate signaling in immune cells and inflammation: roles and therapeutic potential. Mediators Infamm. 2016;2016:1–11. doi: 10.1155/2016/8606878
   Web of Science ®Google Scholar
• Wang W, Graeler MH, Goetzl EJ. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J. 2005;19:1731–1733. doi: 10.1096/fj.05-3730fje
   PubMed Web of Science ®Google Scholar
• Olesch C, Ringel C, Brüne B, et al. Beyond immune cell migration: the emerging role of the sphingosine-1-phosphate receptor S1PR4 as a modulator of innate immune cell activation. Mediat Infamm. 2017;2017:1–12. doi: 10.1155/2017/6059203
   Web of Science ®Google Scholar
• Jenne CN, Enders A, Rivera R, et al. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med. 2009;206(11):2469–2481. doi: 10.1084/jem.20090525
   PubMed Web of Science ®Google Scholar
• Zeposia: EPAR. n.d 2023; https://www.ema.europa.eu/en/documents/productinformation/zeposia-epar-product-information_en.pdf
   Google Scholar
• Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159–1171. doi: 10.1016/S0140-6736(23)00061-2
   PubMed Web of Science ®Google Scholar
• Mitroulis I, Alexaki VI, Kourtzelis I, et al. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther. 2015;147:123–135. doi: 10.1016/j.pharmthera.2014.11.008
   PubMed Web of Science ®Google Scholar
• Herter J, Zarbock A. Recruitment integrin regulation during leukocyte. J Immunol. 2019;190(9):4451–4457. doi: 10.4049/jimmunol.1203179
   Google Scholar
• Li H, Huang SY, Shi H, et al. α4β7 integrin inhibitors: a patent review. Expert Opin Ther Pat. 2018;28(12):903–917. doi: 10.1080/13543776.2018.1549227
   PubMed Web of Science ®Google Scholar
• Zundler S, Fischer A, Schillinger D, et al. The α4β1 homing pathway is essential for ileal homing of crohnʼs disease effector T cells in vivo. Inflamm Bowel Dis. 2017;23(3):379–391. doi: 10.1097/MIB.0000000000001029
   PubMed Web of Science ®Google Scholar
• Baiula M, Spampinato S, Gentilucci L, et al. Novel Ligands Targeting α4β1 Integrin: Therapeutic applications and perspectives. Front Chem. 2019;7:489. doi: 10.3389/fchem.2019.00489
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kageyama S, Andou A, et al. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013;7(11):e533–e542. doi: 10.1016/j.crohns.2013.03.014
   PubMedGoogle Scholar
• Matsuoka K, Watanabe M, Ohmori T., et al. AJM300 Study Group. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(7):648–657.
   PubMed Web of Science ®Google Scholar
• Tazi J, Begon-Pescia C, Campos N, et al. Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases. Drug Discov Today. 2021;26(4):1030–1039. doi: 10.1016/j.drudis.2020.12.019
   PubMed Web of Science ®Google Scholar
• Vermeire S, Sands BE, Tilg H, et al. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol Hepatol. 2022;7(11):1024–1035. doi: 10.1016/S2468-1253(22)00233-3
   PubMed Web of Science ®Google Scholar
• Banerjee R, Sharma V, Patel R, et al. Tofacitinib use in ulcerative colitis: an expert consensus for day-to-day clinical practice. Indian J Gastroenterol. 2024;43(1):22–35. doi: 10.1007/s12664-023-01507-9
   PubMed Web of Science ®Google Scholar